Synergistic action of naringenin and amikacin in the treatment of avian colibacillosis
- 1College of Life Science and Food Engineering, Hebei University of Engineering, Hanshan District, Handan, 056038 China
Abstract
Background: Avian colibacillosis is an infectious disease caused by pathogenic Escherichia coli (E. coli) and is one of the significant causes of economic losses in the global poultry industry. The overuse of antibiotics has led to the emergence of resistant strains, and the presence of antibiotic residues in chickens and eggs poses a threat to human health. Therefore, exploring safe adjuvants to enhance the efficacy of existing antibiotics is one of the critical issues in poultry farming and public health research. Naringenin (NG), a naturally occurring flavonoid, has been extensively studied as a therapeutic agent for various diseases, but its efficacy in combination with antibiotics for treating avian colibacillosis has not yet been explored.
Results: In this study, we established a model of avian colibacillosis and treated it with NG and amikacin (AMK) alone or in combination. Compared with monotherapy, the combination of NG and AMK significantly decreased bacterial loads in the heart, liver, spleen, lung, and kidney by 5.0–6.0 log10 CFU/g (p < 0.01). Histopathological analysis revealed that the combination treatment markedly alleviated pathological damage in the lung and duodenum compared to the AMK alone group. Furthermore, the combination therapy significantly exerted anti-inflammatory and antioxidant effects, as evidenced by reduced serum levels of tumor necrosis factor-alpha (TNF-α), interleukin-1 beta (IL-1β), and malondialdehyde (MDA), alongside increased superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px) activities (p < 0.05). 16 S rRNA sequencing demonstrated that the combination treatment significantly modulated the gut microbiota composition, decreasing the relative abundance of Proteobacteria from 44% in the infection group to 1.2% (p < 0.01), while increasing Firmicutes and Bacteroidetes to levels comparable to healthy controls.
Conclusions: The research results provides evidence for the therapeutic potential of NG as an effective antibiotic synergist when combined with AMK against avian colibacillosis.
Related
- Nanomolar anti-SARS-CoV-2 Omicron activity of the host-directed TMPRSS2 inhibitor N-0385 and synergistic action with direct-acting antivirals
- Synergistic activity of Ginsenoside Rh2 with β-lactam antibiotics and its mechanism of action against methicillin-resistant Staphylococcus aureus
- Targeted dual-responsive nanocapsules for synergistic cisplatin and paclitaxel prodrug delivery in the treatment of lung cancer
- Ultrastructural Signatures of Amikacin Neurotoxicity and the Protective Modulation of Memantine in Peripheral Nerves: A Transmission Electron Microscopy Exploration in Wistar Rats
- Combinatorial treatment with formononetin and magnolol induces synergistic cytotoxicity and suppresses migration in glioblastoma cells
BibTeX
@article{yi2026synergistic,
title = {{Synergistic action of naringenin and amikacin in the treatment of avian colibacillosis}},
author = {Lankun Yi and Xu Chen and Zhen Zhu and Qing Liu and Yang Huang and Jianing Pang and Zeyu Wang and Ding Guan and Tenghe Ma and Mingze Cao and Yongbiao Wan},
journal = {BMC Veterinary Research},
year = {2026},
month = jul,
doi = {10.1186/s12917-026-05745-9},
url = {https://doi.org/10.1186/s12917-026-05745-9},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - Synergistic action of naringenin and amikacin in the treatment of avian colibacillosis
AU - Lankun Yi
AU - Xu Chen
AU - Zhen Zhu
AU - Qing Liu
AU - Yang Huang
AU - Jianing Pang
AU - Zeyu Wang
AU - Ding Guan
AU - Tenghe Ma
AU - Mingze Cao
AU - Yongbiao Wan
PY - 2026
DA - 2026/07/25
JO - BMC Veterinary Research
DO - 10.1186/s12917-026-05745-9
UR - https://doi.org/10.1186/s12917-026-05745-9
AB - Background: Avian colibacillosis is an infectious disease caused by pathogenic Escherichia coli (E. coli) and is one of the significant causes of economic losses in the global poultry industry. The overuse of antibiotics has led to the emergence of resistant strains, and the presence of antibiotic residues in chickens and eggs poses a threat to human health. Therefore, exploring safe adjuvants to enhance the efficacy of existing antibiotics is one of the critical issues in poultry farming and public health research. Naringenin (NG), a naturally occurring flavonoid, has been extensively studied as a therapeutic agent for various diseases, but its efficacy in combination with antibiotics for treating avian colibacillosis has not yet been explored. Results: In this study, we established a model of avian colibacillosis and treated it with NG and amikacin (AMK) alone or in combination. Compared with monotherapy, the combination of NG and AMK significantly decreased bacterial loads in the heart, liver, spleen, lung, and kidney by 5.0–6.0 log10 CFU/g (p < 0.01). Histopathological analysis revealed that the combination treatment markedly alleviated pathological damage in the lung and duodenum compared to the AMK alone group. Furthermore, the combination therapy significantly exerted anti-inflammatory and antioxidant effects, as evidenced by reduced serum levels of tumor necrosis factor-alpha (TNF-α), interleukin-1 beta (IL-1β), and malondialdehyde (MDA), alongside increased superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px) activities (p < 0.05). 16 S rRNA sequencing demonstrated that the combination treatment significantly modulated the gut microbiota composition, decreasing the relative abundance of Proteobacteria from 44% in the infection group to 1.2% (p < 0.01), while increasing Firmicutes and Bacteroidetes to levels comparable to healthy controls. Conclusions: The research results provides evidence for the therapeutic potential of NG as an effective antibiotic synergist when combined with AMK against avian colibacillosis.
SN - 1746-6148
ER -